Targeting Radiation to Tumours

References

• Amin A.E., Wheldon T.E., O'Donoghue J.A., Barrett A. Radiobiological modelling of combined targeted 131I therapy and total body irradiation for treatment of disseminated tumours of differing radiosensitivity. International Journal of Radiation Oncology, Biology and Physics 1993, in press
   PubMedGoogle Scholar
• Andersson A., Capala J., Carlsson J. Effects of EGF -dextran -tyrosine 131I conjugates on the clonogenic survival of cultured glioma cells. Journal of Neurological Oncology 1992; 14: 213–223
   PubMed Web of Science ®Google Scholar
• Barth R.F., Soloway A.H., Fairchild R.G. Boron neutron capture therapy of cancer. Cancer Research 1990; 50: 1061–1070
   PubMed Web of Science ®Google Scholar
• Bigner S.H., Burger P.C., Wong A.J., Werner M.H., Hamilton S.R., Mulbaier L.H., Vogelstein B., Bigner D.D. Gene amplification in malignant human gliomas: clinical and histopathological aspects. Journal of Neuropathology and Experimental Neurology 1988; 47: 191–205
   PubMed Web of Science ®Google Scholar
• Capala J., Carlsson J. Influence of chloroquine and lidocaine on retention and therapeutic effects of 131I-EGF: studies on cultured glioma cells. International Journal of Radiation Biology 1991; 60: 497–510
   PubMed Web of Science ®Google Scholar
• Dale R.G. The application of the linear quadratic dose-effect equation to fractionated and protracted radiotherapy. British Journal of Radiology 1985; 58: 515–528
   PubMed Web of Science ®Google Scholar
• De Sombre E.R., Shafft B., Hanson R.N., Kulvanen P.C., Hughes A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Research 1992; 52: 5752–5758
   PubMedGoogle Scholar
• Fowler J.F. Radiobiological aspects of low dose rates in radioimmunotherapy. International Journal of Radiation Oncology Biology and Physics 1990; 18: 1261–1269
   PubMed Web of Science ®Google Scholar
• Gaze M.N., Mairs R.J., Boyack S.M., Wheldon T.E., Barrett A. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. British Journal of Cancer 1992; 66: 1045–1052
   Google Scholar
• Griffith M.H., Yorke E.D., Wessels B.W., De Nardo G.L., Neacy W.P. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. Journal of Nuclear Medicine 1988; 29: 1795–1809
   PubMed Web of Science ®Google Scholar
• Hand P.H., Nuti M., Cokher D., Schlom J. Definition of antigenic heterogeneity and modulation amongst human mammary carcinoma cell populations to tumour associated antigens. Cancer Research 1983; 43: 728–735
   PubMed Web of Science ®Google Scholar
• Helene C. The anti-gene strategy: control of gene expression by triplex-forming oligonucleotides. Anti-Cancer Drug Design 1991; 6: 569–584
   PubMedGoogle Scholar
• Hird V., Snook D., Cosmas C., Epenetus A.A. Intraperitoneal radioimmunotherapy with stable immunoconjugates of 90Y. Advances in the Application of Monoclonal Antibodies in Clinical Oncology, A.A. Epenetos. Chapman & Hall, London 1991a; 267–272, In
   Google Scholar
• Hird V., Verhoeyen M., Badley R.A., Price D., Snook D., Kosmas C., Gooden C., Bamias A., Meares C., Lavender J.P., Epenetos A.A. Tumour localisation with a radioactively reshaped human monoclonal antibody. British Journal of Cancer 1991b; 64: 911–914
   PubMed Web of Science ®Google Scholar
• Humm J.L. Dosimetric aspects of radiolabelled antibodies for tumour therapy. Journal of Nuclear Medicine 1986; 9: 1490–1497
   Google Scholar
• Humm J.L., Charlton D.E. A new calculational method to assess the therapeutic potential of Auger electron emissions. International Journal of Radiation Onocology, Biology and Physics 1989; 17: 351–360
   PubMed Web of Science ®Google Scholar
• Langmuir V.K., Fowler J.F., Knox S.J., Wessels B.W., Sutherland R.M., Wong J.Y.C. Radiobiology of radiolabelled antibody therapy as applied to tumour dosimetry. Medical Physics 1993; 20: 601–610
   PubMedGoogle Scholar
• Lashford L.S., Davies A.G., Richardson R.B., Bourne S.B., Bullimore J.A., Eckert H., Kemshead J.T., Coakham H.B. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumours. Cancer 1988; 61: 857–868
   PubMed Web of Science ®Google Scholar
• Lewis I.J., Lashford L.S., Fieldings S., Flower M.A., Ackery D., Kemshead J.T. A phase I/II study of 131I-mIBG in chemoresistant neuroblastoma. Advances in Neuroblastoma Research 3, A.E. Evans, G.J. D'Angio, A.G. Knudson, Jr, R.C. Seeger. Wiley-Liss. 1991; 463–470, In
   Google Scholar
• Mairs R.J., Angerson W., Gaze M.N., Murray T., Babich J.W., Reid R., McSharry C. The distribution of alternative agents within human neuroblastoma spheroids. British Journal of Cancer 1991; 63: 404–409
   PubMedGoogle Scholar
• Millar W.T. Application of the linear-quadratic model with incomplete repair to radionuclide-directed therapy. British Journal of Radiology 1991; 64: 242–252
   PubMed Web of Science ®Google Scholar
• Moore J.V., Yan C.Y., West C.M. Role of the LDL receptor pathway in the uptake of drugs used in photochemotherapy. International Journal of Radiation Biology 1993; 65: 134–134, (Abs.)
   Google Scholar
• Moyes J.S.E., Babich J.W., Carter R., Meller S.T., Agrawal M., McElwain T.J. A quantitative study of meta-iodo-benzylguanidine (mIBG) uptake in children with neuroblastoma: correlation with tumour histopathology. Journal of Nuclear Medicine 1989; 30: 474–480
   PubMed Web of Science ®Google Scholar
• O'Donoghue J.A. Optimum scheduling of biologically targeted radiotherapy and total body irradiation with bone marrow rescue for the treatment of systemic malignant disease. International Journal of Radiation Oncology, Biology and Physics 1991; 21: 1587–1594
   PubMedGoogle Scholar
• O'Donoghue J.A., Bardies M. Optimal tumour cure sizes for targeted radiotherapy. International Journal of Radiation Biology 1993; 65: 133–133, (Abs.)
   Google Scholar
• Ozanne B.W., Richards C.S., Hendler F.J., Burns D., Gustersen B. Over-expression of the EGF receptor is a hall-mark of squamous cell carcinomas. Journal of Pathology 1986; 149: 9–14
   PubMed Web of Science ®Google Scholar
• Pedley R.B., Begant R.H.J., Boden J.A., Adam T., Bagshawe K.D. The effect of radiosensitisers on radioimmunotherapy using 131I labelled anti-CEA antibodies in a human colonic cancer xenograft model. International Journal of Cancer 1991; 47: 597–602
   PubMedGoogle Scholar
• Pervez S., Kirkland S.C., Epenetos A.A., Mool W.J., Evans D.J., Krausz T. Effect of polarity and differentiation in multicellular tumour spheroid and xenograft models and its potential importance for in vivo immunotargeting. International Journal of Cancer 1989; 44: 940–947
   PubMed Web of Science ®Google Scholar
• Riordon M., Martin J.C. Oligonucleotide-based therapeutics. Nature 1991; 350: 442–442
   Google Scholar
• Steel G.G. The dose rate effect: brachytherapy. The ESTRO Book of Basic Clinical Radiobiology, G.G. Steel. Edward Arnold, London 1993; 120–129, In
   Google Scholar
• Stewart F.A., van Zandwijk N. Photodynamic Therapy. Basic Clinical Radiobiology, G.G. Steel. Edward Arnold, London 1993; 194–200, In
   Google Scholar
• Voute P.A., Hoefnagel C.A., de Kranker J., Valdes-Omas R., Bakker D.J., van deKleu A.J. Results of treatment with meta-iodobenzylguanidine (131I-mIBG) in patients with neuroblastoma: future prospects of zetotherapy. Advances in Neuroblastoma Research 3, A.E. Evans, G.J. D'Angio, A.G. Knudson, Jr., R.C. Seeger. Wiley-Liss, New York/London 1991; 439–446, In
   Google Scholar
• Wessels B., Rogus R. Radionuclide selection and model absorbed dose calculations for radiolabelled tumour associated antibodies. Medical Physics 1984; 11: 638–642
   PubMed Web of Science ®Google Scholar
• Wheldon T.E., O'Donoghue J.A. The radiobiology of targeted radiotherapy. International Journal of Radiation Biology 1990; 58: 1–21
   PubMed Web of Science ®Google Scholar
• Wheldon T.E., O'Donoghue J.A., Barrett A., Michalowski A.S. The curability of tumours of differing size by targeted radiotherapy using 131I and 90Y. Radiotherapy and Oncology 1991; 21: 91–99
   PubMed Web of Science ®Google Scholar
• Wheldon T.E., Amin A.E., O'Donoghue J.A., Barrett A. Radiocurability of disseminated malignant disease by external beam irradiation and targeted radionuclide therapy. Monoclonal Antibodies 3: Applications in Clinical Oncology, A.A. Epentos. Chapman & Hall, London 1993; 245–254, In
   Google Scholar